IMRX logo

IMRX
Immuneering Corp

2,685
Mkt Cap
$430.04M
Volume
1.43M
52W High
$10.08
52W Low
$1.10
PE Ratio
-3.73
IMRX Fundamentals
Price
$6.73
Prev Close
$6.66
Open
$6.67
50D MA
$6.47
Beta
1.35
Avg. Volume
1.18M
EPS (Annual)
-$2.04
P/B
1.85
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
All You Need to Know About Immuneering (IMRX) Rating Upgrade to Buy
Immuneering (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Wall Street Zen Downgrades Immuneering (NASDAQ:IMRX) to Sell
Wall Street Zen lowered Immuneering from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·11d ago
News Placeholder
Immuneering Corporation (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have been given an average rating of "Moderate Buy" by the eight analysts that are covering the stock, Marketbeat reports. One...
MarketBeat·18d ago
News Placeholder
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance PR Newswire VANCOUVER, BC, Dec. 12, 2025 Issued on behalf...
PR Newswire·18d ago
News Placeholder
Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock?
Immuneering (IMRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
News Placeholder
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High?
The mean of analysts' price targets for Immuneering (IMRX) points to a 126.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·1mo ago
News Placeholder
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts
Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the firm...
MarketBeat·1mo ago
News Placeholder
Immuneering (NASDAQ:IMRX) Given "Buy" Rating at Chardan Capital
Chardan Capital reissued a "buy" rating and set a $20.00 target price on shares of Immuneering in a research report on Thursday...
MarketBeat·2mo ago
News Placeholder
Immuneering (NASDAQ:IMRX) Announces Quarterly Earnings Results
Immuneering (NASDAQ:IMRX - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.03...
MarketBeat·2mo ago
News Placeholder
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.
Zacks·2mo ago
<
1
2
...
>

Latest IMRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.